Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. 2007

Yoshio Tano, and Hiroyuki Shimizu, and Javier Martin, and Yorihiro Nishimura, and Bunsiti Simizu, and Tatsuo Miyamura
Department of Virology II, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama-shi, Tokyo 208-0011, Japan; Japan Poliomyelitis Research Institute, Kumegawa-cho 5-34-4, Higashimurayama-shi, Tokyo 189-0003, Japan.

A candidate inactivated poliovirus vaccine derived from live-attenuated Sabin strains (sIPV), which are used in the oral poliovirus vaccine (OPV), was prepared in a large-production scale. The modification of viral antigenic epitopes during the formalin inactivation process was investigated by capture ELISA assays using type-specific and antigenic site-specific monoclonal antibodies (MoAbs). The major antigenic site 1 was modified during the formalin inactivation of Sabin 1. Antigenic sites 1-3 were slightly modified during the formalin inactivation of Sabin 2 strain. Sites 1 and 3 were altered on inactivated Sabin 3 virus. These alterations were different to those shown by wild-type Saukett strain, used in conventional IPV (cIPV). It has been previously reported that type 1 sIPV showed higher immunogenicity to type 1 cIPV whereas types 2 and 3 sIPV induced lower level of immunogenicity than their cIPV counterparts. Our results suggest that the differences in epitope structure after formalin inactivation may account, at least in part, for the observed differences in immunogenicity between Sabin and wild-type inactivated poliovaccines.

UI MeSH Term Description Entries
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011054 Poliovirus Vaccine, Inactivated A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS. Salk Vaccine,Inactivated Poliovirus Vaccine,Vaccine, Inactivated Poliovirus,Vaccine, Salk
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005557 Formaldehyde A highly reactive aldehyde gas formed by oxidation or incomplete combustion of hydrocarbons. In solution, it has a wide range of uses: in the manufacture of resins and textiles, as a disinfectant, and as a laboratory fixative or preservative. Formaldehyde solution (formalin) is considered a hazardous compound, and its vapor toxic. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p717) Formalin,Formol,Methanal,Oxomethane
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Yoshio Tano, and Hiroyuki Shimizu, and Javier Martin, and Yorihiro Nishimura, and Bunsiti Simizu, and Tatsuo Miyamura
June 2006, Biologicals : journal of the International Association of Biological Standardization,
Yoshio Tano, and Hiroyuki Shimizu, and Javier Martin, and Yorihiro Nishimura, and Bunsiti Simizu, and Tatsuo Miyamura
February 2020, The Journal of infectious diseases,
Yoshio Tano, and Hiroyuki Shimizu, and Javier Martin, and Yorihiro Nishimura, and Bunsiti Simizu, and Tatsuo Miyamura
July 2003, The Journal of general virology,
Yoshio Tano, and Hiroyuki Shimizu, and Javier Martin, and Yorihiro Nishimura, and Bunsiti Simizu, and Tatsuo Miyamura
May 2011, Expert review of vaccines,
Yoshio Tano, and Hiroyuki Shimizu, and Javier Martin, and Yorihiro Nishimura, and Bunsiti Simizu, and Tatsuo Miyamura
November 2016, Biologicals : journal of the International Association of Biological Standardization,
Yoshio Tano, and Hiroyuki Shimizu, and Javier Martin, and Yorihiro Nishimura, and Bunsiti Simizu, and Tatsuo Miyamura
January 2001, Developments in biologicals,
Yoshio Tano, and Hiroyuki Shimizu, and Javier Martin, and Yorihiro Nishimura, and Bunsiti Simizu, and Tatsuo Miyamura
September 2011, Vaccine,
Yoshio Tano, and Hiroyuki Shimizu, and Javier Martin, and Yorihiro Nishimura, and Bunsiti Simizu, and Tatsuo Miyamura
June 1986, Uirusu,
Yoshio Tano, and Hiroyuki Shimizu, and Javier Martin, and Yorihiro Nishimura, and Bunsiti Simizu, and Tatsuo Miyamura
June 1993, Biologicals : journal of the International Association of Biological Standardization,
Yoshio Tano, and Hiroyuki Shimizu, and Javier Martin, and Yorihiro Nishimura, and Bunsiti Simizu, and Tatsuo Miyamura
April 1999, Vaccine,
Copied contents to your clipboard!